Get the Stockscreener App
302.51
2.33%
-7.60
Praxis Precision Medicines Inc stock is traded at $302.51, with a volume of 224.76K.
It is down -2.33% in the last 24 hours and down -2.52% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$310.11
Open:
$309.41
24h Volume:
224.76K
Relative Volume:
0.47
Market Cap:
$8.40B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-22.46
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-5.99%
1M Performance:
-2.52%
6M Performance:
+482.02%
1Y Performance:
+860.62%
1-Day Range:
$300.57
$310.00
1-Week Range:
$300.57
$338.31
52-Week Range:
$26.70
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
301.60 | 8.64B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
430.87 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.96 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
761.47 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.58 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.57 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com India
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial - Benzinga
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Investing News Network
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - marketbeat.com
(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance UK
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Praxis Precision Medicines, Inc. (PRAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
PRAX SEC FilingsPraxis Precision Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 13.4%Time to Buy? - MarketBeat
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525 - Moomoo
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - MSN
FDA Prioritizes Review of Praxis Precision's (PRAX) Drug Applica - gurufocus.com
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine - marketscreener.com
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs - Bitget
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial - MarketBeat
(PRAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - AOL.com
Aug Swings: Is Praxis Precision Medicines Inc forming bullish engulfing patterns2026 Reactions & Reliable Momentum Entry Alerts - baoquankhu1.vn
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - AOL.com
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 FilingNews and Statistics - IndexBox
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - AOL.com
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? - Yahoo Finance
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.92%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):